agonist pnu 282987  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Alomone Labs agonist pnu 282987
    α7nAChR agonist treatment ameliorates STZ-induced diabetes in mice. A , weekly fed-blood glucose levels of STZ-induced or control mice subjected to daily injections of 10 mg/kg <t>PNU-282987</t> or vehicle (4-week cohort). The mean values are indicated by red bars. B , PNU treatment improves glucose tolerance in MLDS mice as shown by IPGTT curves ; and C , the corresponding area under curve ( AUC ) plots. All p values (using one-way analysis of variance) are indicated. The 4-day and 2-week cohorts were distinct from the mice used for the 4-week group. All groups, n = 5.
    Agonist Pnu 282987, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/agonist pnu 282987/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    agonist pnu 282987 - by Bioz Stars, 2022-08
    90/100 stars

    Images

    1) Product Images from "β-Cell mass restoration by α7 nicotinic acetylcholine receptor activation"

    Article Title: β-Cell mass restoration by α7 nicotinic acetylcholine receptor activation

    Journal: The Journal of Biological Chemistry

    doi: 10.1074/jbc.RA118.004617

    α7nAChR agonist treatment ameliorates STZ-induced diabetes in mice. A , weekly fed-blood glucose levels of STZ-induced or control mice subjected to daily injections of 10 mg/kg PNU-282987 or vehicle (4-week cohort). The mean values are indicated by red bars. B , PNU treatment improves glucose tolerance in MLDS mice as shown by IPGTT curves ; and C , the corresponding area under curve ( AUC ) plots. All p values (using one-way analysis of variance) are indicated. The 4-day and 2-week cohorts were distinct from the mice used for the 4-week group. All groups, n = 5.
    Figure Legend Snippet: α7nAChR agonist treatment ameliorates STZ-induced diabetes in mice. A , weekly fed-blood glucose levels of STZ-induced or control mice subjected to daily injections of 10 mg/kg PNU-282987 or vehicle (4-week cohort). The mean values are indicated by red bars. B , PNU treatment improves glucose tolerance in MLDS mice as shown by IPGTT curves ; and C , the corresponding area under curve ( AUC ) plots. All p values (using one-way analysis of variance) are indicated. The 4-day and 2-week cohorts were distinct from the mice used for the 4-week group. All groups, n = 5.

    Techniques Used: Mouse Assay

    The glycemic improvement in PNU-282987–treated mice is a result of preserved β-cell mass. A , morphometric analysis reveals that although BCM is reduced 50% in the STZ control mice (#) compared with its respective control group after 4 weeks, the PNU-treated STZ mice showed no significant reduction in BCM (##) compared with the Veh/Veh and PNU/Veh groups. However, a 60% higher BCM (*, p
    Figure Legend Snippet: The glycemic improvement in PNU-282987–treated mice is a result of preserved β-cell mass. A , morphometric analysis reveals that although BCM is reduced 50% in the STZ control mice (#) compared with its respective control group after 4 weeks, the PNU-treated STZ mice showed no significant reduction in BCM (##) compared with the Veh/Veh and PNU/Veh groups. However, a 60% higher BCM (*, p

    Techniques Used: Mouse Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Alomone Labs agonist pnu 282987
    α7nAChR agonist treatment ameliorates STZ-induced diabetes in mice. A , weekly fed-blood glucose levels of STZ-induced or control mice subjected to daily injections of 10 mg/kg <t>PNU-282987</t> or vehicle (4-week cohort). The mean values are indicated by red bars. B , PNU treatment improves glucose tolerance in MLDS mice as shown by IPGTT curves ; and C , the corresponding area under curve ( AUC ) plots. All p values (using one-way analysis of variance) are indicated. The 4-day and 2-week cohorts were distinct from the mice used for the 4-week group. All groups, n = 5.
    Agonist Pnu 282987, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/agonist pnu 282987/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    agonist pnu 282987 - by Bioz Stars, 2022-08
    90/100 stars
      Buy from Supplier

    96
    Alomone Labs anti trpv1
    Expression levels of <t>TRPV1,</t> p-PI3K, p-CREB and p-PKAIIα in the NTS. (A) Representative immunofluorescence staining of TRPV1 (green) and p-PKAIIα (red) and (B) representative immunofluorescence staining of p-PI3K (red) and p-CREB (green) were performed in the NTS of subjects in the WT-HFD, WT-HFD-ACE, WT-HFD-SHAM and KO-HFD groups. White arrowheads indicate immunopositive cells. TRPV1, transient receptor vanilloid member 1; WT, wild-type; ND, normal diet; HFD, high-fat diet; ACE, acupoint catgut embedding; KO, knockout; p, phosphorylated; PKAIIα, protein kinase AII α; CREB, cyclic AMP-response element binding protein; NTS, nucleus tractus solitarii.
    Anti Trpv1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv1/product/Alomone Labs
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv1 - by Bioz Stars, 2022-08
    96/100 stars
      Buy from Supplier

    Image Search Results


    α7nAChR agonist treatment ameliorates STZ-induced diabetes in mice. A , weekly fed-blood glucose levels of STZ-induced or control mice subjected to daily injections of 10 mg/kg PNU-282987 or vehicle (4-week cohort). The mean values are indicated by red bars. B , PNU treatment improves glucose tolerance in MLDS mice as shown by IPGTT curves ; and C , the corresponding area under curve ( AUC ) plots. All p values (using one-way analysis of variance) are indicated. The 4-day and 2-week cohorts were distinct from the mice used for the 4-week group. All groups, n = 5.

    Journal: The Journal of Biological Chemistry

    Article Title: β-Cell mass restoration by α7 nicotinic acetylcholine receptor activation

    doi: 10.1074/jbc.RA118.004617

    Figure Lengend Snippet: α7nAChR agonist treatment ameliorates STZ-induced diabetes in mice. A , weekly fed-blood glucose levels of STZ-induced or control mice subjected to daily injections of 10 mg/kg PNU-282987 or vehicle (4-week cohort). The mean values are indicated by red bars. B , PNU treatment improves glucose tolerance in MLDS mice as shown by IPGTT curves ; and C , the corresponding area under curve ( AUC ) plots. All p values (using one-way analysis of variance) are indicated. The 4-day and 2-week cohorts were distinct from the mice used for the 4-week group. All groups, n = 5.

    Article Snippet: The partial agonist GTS-21 (Tocris Bioscience) and the specific agonist PNU-282987 (Alomone Labs) were used for α7R activation, whereas MLA (Tocris) was used as a specific α7R antagonist.

    Techniques: Mouse Assay

    The glycemic improvement in PNU-282987–treated mice is a result of preserved β-cell mass. A , morphometric analysis reveals that although BCM is reduced 50% in the STZ control mice (#) compared with its respective control group after 4 weeks, the PNU-treated STZ mice showed no significant reduction in BCM (##) compared with the Veh/Veh and PNU/Veh groups. However, a 60% higher BCM (*, p

    Journal: The Journal of Biological Chemistry

    Article Title: β-Cell mass restoration by α7 nicotinic acetylcholine receptor activation

    doi: 10.1074/jbc.RA118.004617

    Figure Lengend Snippet: The glycemic improvement in PNU-282987–treated mice is a result of preserved β-cell mass. A , morphometric analysis reveals that although BCM is reduced 50% in the STZ control mice (#) compared with its respective control group after 4 weeks, the PNU-treated STZ mice showed no significant reduction in BCM (##) compared with the Veh/Veh and PNU/Veh groups. However, a 60% higher BCM (*, p

    Article Snippet: The partial agonist GTS-21 (Tocris Bioscience) and the specific agonist PNU-282987 (Alomone Labs) were used for α7R activation, whereas MLA (Tocris) was used as a specific α7R antagonist.

    Techniques: Mouse Assay

    Expression levels of TRPV1, p-PI3K, p-CREB and p-PKAIIα in the NTS. (A) Representative immunofluorescence staining of TRPV1 (green) and p-PKAIIα (red) and (B) representative immunofluorescence staining of p-PI3K (red) and p-CREB (green) were performed in the NTS of subjects in the WT-HFD, WT-HFD-ACE, WT-HFD-SHAM and KO-HFD groups. White arrowheads indicate immunopositive cells. TRPV1, transient receptor vanilloid member 1; WT, wild-type; ND, normal diet; HFD, high-fat diet; ACE, acupoint catgut embedding; KO, knockout; p, phosphorylated; PKAIIα, protein kinase AII α; CREB, cyclic AMP-response element binding protein; NTS, nucleus tractus solitarii.

    Journal: International Journal of Molecular Medicine

    Article Title: Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model

    doi: 10.3892/ijmm.2020.4462

    Figure Lengend Snippet: Expression levels of TRPV1, p-PI3K, p-CREB and p-PKAIIα in the NTS. (A) Representative immunofluorescence staining of TRPV1 (green) and p-PKAIIα (red) and (B) representative immunofluorescence staining of p-PI3K (red) and p-CREB (green) were performed in the NTS of subjects in the WT-HFD, WT-HFD-ACE, WT-HFD-SHAM and KO-HFD groups. White arrowheads indicate immunopositive cells. TRPV1, transient receptor vanilloid member 1; WT, wild-type; ND, normal diet; HFD, high-fat diet; ACE, acupoint catgut embedding; KO, knockout; p, phosphorylated; PKAIIα, protein kinase AII α; CREB, cyclic AMP-response element binding protein; NTS, nucleus tractus solitarii.

    Article Snippet: Proteins from each sample were loaded into 8% SDS-Tris glycine gel electrophoresis gels and transferred onto PVDF membranes, which were then blocked with 5% non-fat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween-20), and incubated for 1 h at room temperature with the following primary antibodies: Anti-TRPV1 (~95 kDa; Alomone; cat. no. ACC-030; 1:1,000), anti-p-PI3K (~110 kDa; Novus Biologicals, LLC; cat. no. NBP2-15071; 1:1,000), anti-PI3K (~126 kDa; Abcam; cat. no. ab154598; 1:1,000), anti-phosphorylated (p)-Akt (~65 kDa, Thermo Fisher Scientific, Inc.; cat. no. 44-621G; 1:1,000), anti-Akt (~65 kDa; Merck KGaA; cat. no. 16-293; 1:1,000), anti-p-mTOR (~289 kDa; Merck KGaA; cat. no. 09-213; 1:1,000), anti-mTOR (~238 kDa; Abcam; cat. no. ab2732; 1:1,000), anti-p-extracellular signal-regulated kinase (ERK) 1/2 (p-ERK)~42 kDa; Abcam; cat. no. ab138482; 1:1,000), anti-ERK (~42-44 kDa; Cell Signaling Technology, Inc.; cat. no. 4695; 1:1,000), anti-p-c-Jun N-terminal kinase (p-JNK; ~45-55 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-682G; 1:1,000), anti-JNK (~46-54 kDa; Cell Signaling Technology, Inc.; cat. no. 9252; 1:1,000), anti-p-p38 mitogen-activated protein kinase (p-p38; ~41 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-684G; 1:1,000), anti-p38 (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9212; 1:1,000), anti-p-NF-κB (~65 kDa; Merck KGaA; cat. no. ABS403; 1:1,000), anti-NF-κB (~65 kDa; Cell Signaling Technology, Inc.; cat. no. 8242; 1:1,000), anti-p-CREB (~43 kDa; Merck KGaA; cat. no. 06-519; 1:1,000), anti-CREB (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9197; 1:1,000), anti-p-protein kinase C epsilon type (p-PKCε; ~82 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12355; 1:1,000), anti-PKCε (~84 kDa; Abcam; cat. no. ab63638; 1:1,000), anti-p-protein kinase AII α (p-PKAIIα; ~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12905; 1:1,000) or anti-PKAIIα (~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-136262; 1:1,000) in TBST with 1% bovine serum albumin (BSA) (Sigma-Aldrich; Merck KGaA).

    Techniques: Expressing, Immunofluorescence, Staining, Knock-Out, Binding Assay

    Expression levels of TRPV1 and associated molecules in the hypothalamus. The expression pattern of TRPV1 protein was detected in the following groups: WT-HFD; WT-HFD-ACE; WT-HFD-SHAM; and KO-HFD. The results revealed significant increases in (A) TRPV1, (B) p-PI3K, (C) p-Akt, (D) p-mTOR, (E) p-PKCε, (F) p-PKAIIα, (G) p-ERK, (H) p-p38, (I) p-JNK, (J) p-NF-κB and (K) p-CREB expression levels in the WT-HFD and WT-HFD-SHAM groups compared with the other groups ( * P

    Journal: International Journal of Molecular Medicine

    Article Title: Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model

    doi: 10.3892/ijmm.2020.4462

    Figure Lengend Snippet: Expression levels of TRPV1 and associated molecules in the hypothalamus. The expression pattern of TRPV1 protein was detected in the following groups: WT-HFD; WT-HFD-ACE; WT-HFD-SHAM; and KO-HFD. The results revealed significant increases in (A) TRPV1, (B) p-PI3K, (C) p-Akt, (D) p-mTOR, (E) p-PKCε, (F) p-PKAIIα, (G) p-ERK, (H) p-p38, (I) p-JNK, (J) p-NF-κB and (K) p-CREB expression levels in the WT-HFD and WT-HFD-SHAM groups compared with the other groups ( * P

    Article Snippet: Proteins from each sample were loaded into 8% SDS-Tris glycine gel electrophoresis gels and transferred onto PVDF membranes, which were then blocked with 5% non-fat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween-20), and incubated for 1 h at room temperature with the following primary antibodies: Anti-TRPV1 (~95 kDa; Alomone; cat. no. ACC-030; 1:1,000), anti-p-PI3K (~110 kDa; Novus Biologicals, LLC; cat. no. NBP2-15071; 1:1,000), anti-PI3K (~126 kDa; Abcam; cat. no. ab154598; 1:1,000), anti-phosphorylated (p)-Akt (~65 kDa, Thermo Fisher Scientific, Inc.; cat. no. 44-621G; 1:1,000), anti-Akt (~65 kDa; Merck KGaA; cat. no. 16-293; 1:1,000), anti-p-mTOR (~289 kDa; Merck KGaA; cat. no. 09-213; 1:1,000), anti-mTOR (~238 kDa; Abcam; cat. no. ab2732; 1:1,000), anti-p-extracellular signal-regulated kinase (ERK) 1/2 (p-ERK)~42 kDa; Abcam; cat. no. ab138482; 1:1,000), anti-ERK (~42-44 kDa; Cell Signaling Technology, Inc.; cat. no. 4695; 1:1,000), anti-p-c-Jun N-terminal kinase (p-JNK; ~45-55 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-682G; 1:1,000), anti-JNK (~46-54 kDa; Cell Signaling Technology, Inc.; cat. no. 9252; 1:1,000), anti-p-p38 mitogen-activated protein kinase (p-p38; ~41 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-684G; 1:1,000), anti-p38 (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9212; 1:1,000), anti-p-NF-κB (~65 kDa; Merck KGaA; cat. no. ABS403; 1:1,000), anti-NF-κB (~65 kDa; Cell Signaling Technology, Inc.; cat. no. 8242; 1:1,000), anti-p-CREB (~43 kDa; Merck KGaA; cat. no. 06-519; 1:1,000), anti-CREB (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9197; 1:1,000), anti-p-protein kinase C epsilon type (p-PKCε; ~82 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12355; 1:1,000), anti-PKCε (~84 kDa; Abcam; cat. no. ab63638; 1:1,000), anti-p-protein kinase AII α (p-PKAIIα; ~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12905; 1:1,000) or anti-PKAIIα (~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-136262; 1:1,000) in TBST with 1% bovine serum albumin (BSA) (Sigma-Aldrich; Merck KGaA).

    Techniques: Expressing

    Expression levels of TRPV1 and associated molecules in the PFC. The expression pattern of TRPV1 protein was detected in the following groups: WT-HFD; WT-HFD-ACE; WT-HFD-SHAM; and KO-HFD. The results demonstrated significant decreases in (A) TRPV1 expression in WT-HFD, WT-HFD-SHAM and KO-HFD groups when compared with the WT-HFD-ACE group, which demonstrated a significant increase following ACE treatment. * P

    Journal: International Journal of Molecular Medicine

    Article Title: Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model

    doi: 10.3892/ijmm.2020.4462

    Figure Lengend Snippet: Expression levels of TRPV1 and associated molecules in the PFC. The expression pattern of TRPV1 protein was detected in the following groups: WT-HFD; WT-HFD-ACE; WT-HFD-SHAM; and KO-HFD. The results demonstrated significant decreases in (A) TRPV1 expression in WT-HFD, WT-HFD-SHAM and KO-HFD groups when compared with the WT-HFD-ACE group, which demonstrated a significant increase following ACE treatment. * P

    Article Snippet: Proteins from each sample were loaded into 8% SDS-Tris glycine gel electrophoresis gels and transferred onto PVDF membranes, which were then blocked with 5% non-fat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween-20), and incubated for 1 h at room temperature with the following primary antibodies: Anti-TRPV1 (~95 kDa; Alomone; cat. no. ACC-030; 1:1,000), anti-p-PI3K (~110 kDa; Novus Biologicals, LLC; cat. no. NBP2-15071; 1:1,000), anti-PI3K (~126 kDa; Abcam; cat. no. ab154598; 1:1,000), anti-phosphorylated (p)-Akt (~65 kDa, Thermo Fisher Scientific, Inc.; cat. no. 44-621G; 1:1,000), anti-Akt (~65 kDa; Merck KGaA; cat. no. 16-293; 1:1,000), anti-p-mTOR (~289 kDa; Merck KGaA; cat. no. 09-213; 1:1,000), anti-mTOR (~238 kDa; Abcam; cat. no. ab2732; 1:1,000), anti-p-extracellular signal-regulated kinase (ERK) 1/2 (p-ERK)~42 kDa; Abcam; cat. no. ab138482; 1:1,000), anti-ERK (~42-44 kDa; Cell Signaling Technology, Inc.; cat. no. 4695; 1:1,000), anti-p-c-Jun N-terminal kinase (p-JNK; ~45-55 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-682G; 1:1,000), anti-JNK (~46-54 kDa; Cell Signaling Technology, Inc.; cat. no. 9252; 1:1,000), anti-p-p38 mitogen-activated protein kinase (p-p38; ~41 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-684G; 1:1,000), anti-p38 (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9212; 1:1,000), anti-p-NF-κB (~65 kDa; Merck KGaA; cat. no. ABS403; 1:1,000), anti-NF-κB (~65 kDa; Cell Signaling Technology, Inc.; cat. no. 8242; 1:1,000), anti-p-CREB (~43 kDa; Merck KGaA; cat. no. 06-519; 1:1,000), anti-CREB (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9197; 1:1,000), anti-p-protein kinase C epsilon type (p-PKCε; ~82 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12355; 1:1,000), anti-PKCε (~84 kDa; Abcam; cat. no. ab63638; 1:1,000), anti-p-protein kinase AII α (p-PKAIIα; ~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12905; 1:1,000) or anti-PKAIIα (~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-136262; 1:1,000) in TBST with 1% bovine serum albumin (BSA) (Sigma-Aldrich; Merck KGaA).

    Techniques: Expressing

    Expression levels of TRPV1, p-PI3K, p-CREB and p-PKAIIα in the hypothalamus. (A) Representative immunofluorescence staining of TRPV1 (green) and p-PKAIIα (red) and (B) representative immunofluorescence staining of p-PI3K (red) and p-CREB (green) were performed in the hypothalamus of subjects in the WT-HFD, WT-HFD-ACE, WT-HFD-SHAM and KO-HFD groups. White arrowheads indicate immunopositive cells. TRPV1, transient receptor vanilloid member 1; WT, wild-type; ND, normal diet; HFD, high-fat diet; ACE, acupoint catgut embedding; KO, knockout; p, phosphorylated; PKAIIα, protein kinase AII α; CREB, cyclic AMP-response element binding protein.

    Journal: International Journal of Molecular Medicine

    Article Title: Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model

    doi: 10.3892/ijmm.2020.4462

    Figure Lengend Snippet: Expression levels of TRPV1, p-PI3K, p-CREB and p-PKAIIα in the hypothalamus. (A) Representative immunofluorescence staining of TRPV1 (green) and p-PKAIIα (red) and (B) representative immunofluorescence staining of p-PI3K (red) and p-CREB (green) were performed in the hypothalamus of subjects in the WT-HFD, WT-HFD-ACE, WT-HFD-SHAM and KO-HFD groups. White arrowheads indicate immunopositive cells. TRPV1, transient receptor vanilloid member 1; WT, wild-type; ND, normal diet; HFD, high-fat diet; ACE, acupoint catgut embedding; KO, knockout; p, phosphorylated; PKAIIα, protein kinase AII α; CREB, cyclic AMP-response element binding protein.

    Article Snippet: Proteins from each sample were loaded into 8% SDS-Tris glycine gel electrophoresis gels and transferred onto PVDF membranes, which were then blocked with 5% non-fat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween-20), and incubated for 1 h at room temperature with the following primary antibodies: Anti-TRPV1 (~95 kDa; Alomone; cat. no. ACC-030; 1:1,000), anti-p-PI3K (~110 kDa; Novus Biologicals, LLC; cat. no. NBP2-15071; 1:1,000), anti-PI3K (~126 kDa; Abcam; cat. no. ab154598; 1:1,000), anti-phosphorylated (p)-Akt (~65 kDa, Thermo Fisher Scientific, Inc.; cat. no. 44-621G; 1:1,000), anti-Akt (~65 kDa; Merck KGaA; cat. no. 16-293; 1:1,000), anti-p-mTOR (~289 kDa; Merck KGaA; cat. no. 09-213; 1:1,000), anti-mTOR (~238 kDa; Abcam; cat. no. ab2732; 1:1,000), anti-p-extracellular signal-regulated kinase (ERK) 1/2 (p-ERK)~42 kDa; Abcam; cat. no. ab138482; 1:1,000), anti-ERK (~42-44 kDa; Cell Signaling Technology, Inc.; cat. no. 4695; 1:1,000), anti-p-c-Jun N-terminal kinase (p-JNK; ~45-55 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-682G; 1:1,000), anti-JNK (~46-54 kDa; Cell Signaling Technology, Inc.; cat. no. 9252; 1:1,000), anti-p-p38 mitogen-activated protein kinase (p-p38; ~41 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-684G; 1:1,000), anti-p38 (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9212; 1:1,000), anti-p-NF-κB (~65 kDa; Merck KGaA; cat. no. ABS403; 1:1,000), anti-NF-κB (~65 kDa; Cell Signaling Technology, Inc.; cat. no. 8242; 1:1,000), anti-p-CREB (~43 kDa; Merck KGaA; cat. no. 06-519; 1:1,000), anti-CREB (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9197; 1:1,000), anti-p-protein kinase C epsilon type (p-PKCε; ~82 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12355; 1:1,000), anti-PKCε (~84 kDa; Abcam; cat. no. ab63638; 1:1,000), anti-p-protein kinase AII α (p-PKAIIα; ~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12905; 1:1,000) or anti-PKAIIα (~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-136262; 1:1,000) in TBST with 1% bovine serum albumin (BSA) (Sigma-Aldrich; Merck KGaA).

    Techniques: Expressing, Immunofluorescence, Staining, Knock-Out, Binding Assay

    Weekly body weight alterations and food consumption in the six subject groups. (A) The graph presents comparisons of body weight in the WT-ND, WT-HFD, WT-HFD-ACE, WT-HFD-SHAM, KO-ND and KO-HFD groups. Significant body weight increases in the WT-HFD, WT-HFD-ACE and WT-HFD-SHAM groups compared to the WT-ND group and both TRPV1 KO mouse groups were observed. * P

    Journal: International Journal of Molecular Medicine

    Article Title: Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model

    doi: 10.3892/ijmm.2020.4462

    Figure Lengend Snippet: Weekly body weight alterations and food consumption in the six subject groups. (A) The graph presents comparisons of body weight in the WT-ND, WT-HFD, WT-HFD-ACE, WT-HFD-SHAM, KO-ND and KO-HFD groups. Significant body weight increases in the WT-HFD, WT-HFD-ACE and WT-HFD-SHAM groups compared to the WT-ND group and both TRPV1 KO mouse groups were observed. * P

    Article Snippet: Proteins from each sample were loaded into 8% SDS-Tris glycine gel electrophoresis gels and transferred onto PVDF membranes, which were then blocked with 5% non-fat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween-20), and incubated for 1 h at room temperature with the following primary antibodies: Anti-TRPV1 (~95 kDa; Alomone; cat. no. ACC-030; 1:1,000), anti-p-PI3K (~110 kDa; Novus Biologicals, LLC; cat. no. NBP2-15071; 1:1,000), anti-PI3K (~126 kDa; Abcam; cat. no. ab154598; 1:1,000), anti-phosphorylated (p)-Akt (~65 kDa, Thermo Fisher Scientific, Inc.; cat. no. 44-621G; 1:1,000), anti-Akt (~65 kDa; Merck KGaA; cat. no. 16-293; 1:1,000), anti-p-mTOR (~289 kDa; Merck KGaA; cat. no. 09-213; 1:1,000), anti-mTOR (~238 kDa; Abcam; cat. no. ab2732; 1:1,000), anti-p-extracellular signal-regulated kinase (ERK) 1/2 (p-ERK)~42 kDa; Abcam; cat. no. ab138482; 1:1,000), anti-ERK (~42-44 kDa; Cell Signaling Technology, Inc.; cat. no. 4695; 1:1,000), anti-p-c-Jun N-terminal kinase (p-JNK; ~45-55 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-682G; 1:1,000), anti-JNK (~46-54 kDa; Cell Signaling Technology, Inc.; cat. no. 9252; 1:1,000), anti-p-p38 mitogen-activated protein kinase (p-p38; ~41 kDa; Thermo Fisher Scientific, Inc.; cat. no. 44-684G; 1:1,000), anti-p38 (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9212; 1:1,000), anti-p-NF-κB (~65 kDa; Merck KGaA; cat. no. ABS403; 1:1,000), anti-NF-κB (~65 kDa; Cell Signaling Technology, Inc.; cat. no. 8242; 1:1,000), anti-p-CREB (~43 kDa; Merck KGaA; cat. no. 06-519; 1:1,000), anti-CREB (~43 kDa; Cell Signaling Technology, Inc.; cat. no. 9197; 1:1,000), anti-p-protein kinase C epsilon type (p-PKCε; ~82 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12355; 1:1,000), anti-PKCε (~84 kDa; Abcam; cat. no. ab63638; 1:1,000), anti-p-protein kinase AII α (p-PKAIIα; ~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-12905; 1:1,000) or anti-PKAIIα (~40 kDa; Santa Cruz Biotechnology, Inc.; cat. no. SC-136262; 1:1,000) in TBST with 1% bovine serum albumin (BSA) (Sigma-Aldrich; Merck KGaA).

    Techniques: